Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Exchange Rate Effect (2016 - 2019)

Coherus Oncology's Exchange Rate Effect history spans 6 years, with the latest figure at -$106000.0 for Q4 2019.

  • For Q4 2019, Exchange Rate Effect fell 176.81% year-over-year to -$106000.0; the TTM value through Mar 2020 reached -$140000.0, down 140.58%, while the annual FY2019 figure was -$276000.0, 158.97% down from the prior year.
  • Exchange Rate Effect for Q4 2019 was -$106000.0 at Coherus Oncology, down from $59000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $226000.0 in Q2 2018 and bottomed at -$271000.0 in Q4 2016.
  • The 5-year median for Exchange Rate Effect is -$28000.0 (2015), against an average of -$12100.0.
  • The largest annual shift saw Exchange Rate Effect surged 2071.43% in 2018 before it plummeted 946.15% in 2019.
  • A 5-year view of Exchange Rate Effect shows it stood at $82000.0 in 2015, then tumbled by 430.49% to -$271000.0 in 2016, then soared by 97.42% to -$7000.0 in 2017, then soared by 2071.43% to $138000.0 in 2018, then tumbled by 176.81% to -$106000.0 in 2019.
  • Per Business Quant, the three most recent readings for CHRS's Exchange Rate Effect are -$106000.0 (Q4 2019), $59000.0 (Q3 2019), and -$93000.0 (Q2 2019).